Is Cartalax FDA approved?

Cartalax is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

Is PTD-DBM FDA approved?

PTD-DBM is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is Cartalax administered in research settings?

In research settings, Cartalax is typically administered via the subcutaneous or oral routes. PeptideBase does not provide dosing or administration instructions.

How is PTD-DBM administered in research settings?

In research settings, PTD-DBM is typically administered via the topical or intradermal routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Cartalax vs PTD-DBM

Peptide Comparison

Cartalax vs PTD-DBM

Name: Cartalax vs PTD-DBM — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Skin & Cosmetic peptides.

Cartalax

Ala-Glu-Asp-Arg

Skin & JointNot EvaluatedResearch Only

Half-life: Unknown

6 providers listed

Full Cartalax profile →

PTD-DBM

Wnt signaling activating peptide

Skin & JointNot EvaluatedResearch Only

7 providers listed

Full PTD-DBM profile →

Bottom line

Cartalax has published research citations on file; PTD-DBM does not yet — the main evidence gap between them.

Quick Verdict

Cartalax

Evidence

Preclinical

PTD-DBM

Evidence

Not rated

Which One Should You Choose?

Your goal	Better option
Has published research citations	Cartalax
Oral administration option	Cartalax
More provider options (6 vs 7)	PTD-DBM

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Cartalax

PTD-DBM

Mechanism Family

Skin & Cosmetic

Half-life

Unknown

—

FDA Status

not evaluated

Admin Routes

subcutaneous, oral

topical, intradermal

Availability

Research Only

Providers

6 listed

7 listed

Avail. Notes

Russian joint/cartilage peptide bioregulator (Khavinson Institute). Not FDA-approved. Not on any FDA list. Research chemical in US.

—

Research Evidence

Cartalax

PreclinicalIn vitro · 1 key study · most recent 2023

PTD-DBM

No citations on file

Research Citations

Cartalax

In vitro2023 · Advances in Gerontology

KE peptide regulates SIRT1, PARP1, PARP2 gene expression and protein synthesis in human mesenchymal stem cell…

PTD-DBM

No citations on file.

About Cartalax

Tetrapeptide bioregulator from cartilage tissue; stimulates chondrocyte proliferation and extracellular matrix synthesis; normalizes gene expression in cartilage cells

Research Areas

cartilage regenerationjoint repairchondrocyte function support

About PTD-DBM

Contains a protein transduction domain enabling intracellular delivery. Disrupts Dishevelled-Axin protein interaction, preventing β-catenin degradation and activating Wnt target genes essential for hair follicle cycling and new follicle neogenesis.

Research Areas

hair regenerationhair follicle activationWnt pathway modulationfollicle neogenesis

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Cartalax

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

PTD-DBM

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Price (per mg)

Cartalax

$2.75/mg

$2.00 – $2.75 range

8 vendors

View price index →Find providers →

PTD-DBM

Not enough vendor pricing yet.

Find Providers

Where to source these peptides

Providers offering

Cartalax

6 listed

Browse directory →

Providers offering

PTD-DBM

7 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Skin & Cosmetic Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated July 27, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). Cartalax vs PTD-DBM — Per-mg Price Comparison. Retrieved July 29, 2026, from https://peptidebase.io/peptides/compare/cartalax/ptd-dbm

https://peptidebase.io/peptides/compare/cartalax/ptd-dbm Methodology License Download JSON Download CSV